-
Ultimovacs ASA: Mandatory notification of trade by primary insider
-
Ultimovacs ASA: New share capital registered
-
Ultimovacs ASA: Share capital increase related to exercise of options
-
Ultimovacs ASA: Mandatory notification of trade by primary insider
-
Ultimovacs ASA Reports Third Quarter 2022 Financial Results and Provides General Business Update
-
Ultimovacs ASA: Invitation to Third quarter 2022 results webcast presentation
-
Ultimovacs Announces First Patient Randomized in Phase II LUNGVAC Trial of UV1 in Non-Small Cell Lung Cancer (NSCLC)
-
Ultimovacs Announces New UV1 Data Showing Enhanced Efficacy Including in Hard-to-Treat Cancer Patients, Supporting Broad Utility
-
Ultimovacs Announces Positive Three-Year Results of 71% Overall Survival Rate in Cohort 1 of UV1-103 Study in Metastatic Malignant Melanoma
-
Ultimovacs Announces Plenary Oral Presentation of Phase I Melanoma Trial Results at the 19th International Congress of the Society for Melanoma Research (SMR)
